Drug Index


Mechanism :

Raltegravir inhibits the catalytic activity of integrase, thus preventing integration of the proviral gene into human DNA.

Indication :

  • Treatment of HIV-1 infection in combination with other antiretroviral agents

Contraindications :

Hypersensitivity to raltegravir or any other component of the formulation

Dosing :

3 to <20 kg: 6 mg/kg/dose PO twice daily; Maximum dose: 300 mg/dose.

Adverse Effect :

Increased serum AST, ALT & cholesterol, increased glucose, hyperbilirubinemia, fatigue, abdominal pain, cough, rash, dizziness, insomnia, vomiting, arthralgia, extremity pain, nausea, diarrhea, pyrexia.

Interaction :

Etravirine: May decrease the serum concentration of Raltegravir.
Fibric Acid Derivatives: Raltegravir may enhance the myopathic (rhabdomyolysis) effect.
HMG-CoA Reductase Inhibitors (Statins): Raltegravir may enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors.
Proton Pump Inhibitors: May increase the serum concentration of Raltegravir.
Rifampin, Rifabutin, Rifapentine: May decrease the serum concentration of Raltegravir.

Hepatic Dose :

Mild to moderate hepatic impairment: No adjustment of dosage recommended
Severe hepatic impairment: Dose reduction is reasonable.
11/03/2023 12:42:21 Raltegravir
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0